We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    factt and fluid and catheter

Fluids and Catheters Treatment Trial (FACTT) - ARDS Clinical Research Network

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00281268
Recruitment Status : Completed
First Posted : January 24, 2006
Last Update Posted : January 21, 2008
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)

Brief Summary:
To assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome as well as those at risk of developing ARDS.

Condition or disease Intervention/treatment Phase
Acute Respiratory Distress Syndrome Lung Diseases Procedure: pulmonary artery catheter Procedure: central venous catheter Procedure: fluid management Phase 3

Detailed Description:


Adult respiratory distress syndrome affects approximately 150,000 people in the United States each year. Despite twenty years of research into the mechanisms that cause this syndrome and numerous developments in the technology of mechanical ventilation, the mortality has remained greater than 50 percent. Many of the patients are young, and in addition to the tragic loss of human life, can be added the cost to society because these patients spend an average of two weeks in intensive care units and require multiple high tech procedures. Because of the overwhelming nature of the lung injury once it is established, prevention would appear to be the most effective strategy for improving the outlook in this condition.

Basic research has identified numerous inflammatory pathways that are associated with the development of ARDS. Agents that block these mediators prolong survival in animals with lung injury, and a few of them have been tested in patients. Because of the large number of putative mediators and the variety of ways that their action can be blocked, the possibility for new drug development is almost infinite. This is an exciting prospect, since it envisions the first effective pharmacologic treatment for ARDS. However, preliminary clinical studies have shown conflicting results, and there is an urgent need for a mechanism to efficiently and effectively test new drugs in ARDS.

Treatment studies in patients with ARDS are difficult to perform for three reasons. The complicated clinical picture makes it difficult to accumulate a large number of comparable patients in any one center. There is no agreement on the optimal supportive care of these critically ill patients. Many of the patients meeting study criteria will not be enrolled in study protocols because of the acute nature of the disease process. For these reasons, therapeutic trials in ARDS require multicenter cooperation.


Network investigators have developed a plan for a new protocol to assess the Pulmonary Artery Catheter as a management tool in ARDS. The new study was prompted by recommendations from the FDA/NIH Pulmonary Artery Catheter Clinical Outcomes workshop convened in August 1997 in response to concerns in the medical community regarding the clinical benefit and safety of pulmonary artery catheters. The new protocol in the Fluids and Catheters Treatment Trial (FACTT) is a two by two factorial design comparing the patients receiving PAC or a central venous catheter (CVC) with one of two fluid management strategies (conservative vs. liberal). The randomized, multicenter trial is designed to include 1000 patients. The primary endpoint is mortality at 60 days. Secondary endpoints include ventilator free days and organ failure free days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Intervention Model: Factorial Assignment
Primary Purpose: Treatment
Actual Primary Completion Date : October 2005
Actual Study Completion Date : October 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   13 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Men and women, 13 years of age or older, with ARDS or risk factors for ARDS. Patients will be considered at risk if they are critically ill and have trauma, sepsis, shock, pneumonia, inhalation injury, drug overdose, pancreatitis, hypertransfusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00281268

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
OverallOfficial: Edward Abraham University of Colorado, Denver
OverallOfficial: Antonio Anzueto University of Texas
OverallOfficial: Alfred Connors University of Virginia
OverallOfficial: Bennett deBoisblanc Louisiana State University Health Sciences Center in New Orleans
OverallOfficial: Michael Donahoe University of Pittsburgh
OverallOfficial: William Fulkerson Duke University
OverallOfficial: Kalpalatha Guntupalli Baylor College of Medicine
OverallOfficial: Robert Hite Wake Forest University
OverallOfficial: Leonard Hudson University of Washington
OverallOfficial: Paul Lanken University of Pennsylvania
OverallOfficial: Michael Matthay University of California
OverallOfficial: Alan Morris Latter Day Saints Hospital
OverallOfficial: James Russell University of British Columbia
OverallOfficial: Gregory Schmidt University of Chicago
OverallOfficial: David Schoenfeld Massachusetts General Hospital
OverallOfficial: Henry Silverman University of Maryland
OverallOfficial: Jay Steingrub Baystate Medical Center
OverallOfficial: Galen Toews University of Michigan
OverallOfficial: Arthur Wheeler Vanderbilt University
OverallOfficial: Herbert Wiedemann The Cleveland Clinic
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00281268    
Other Study ID Numbers: 356
First Posted: January 24, 2006    Key Record Dates
Last Update Posted: January 21, 2008
Last Verified: January 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury